Research Article

Overexpressed C14orf166 associates with disease progression and poor prognosis in non-small-cell lung cancer

Yan-Wu Zhou, Rong Li, Chao-Jun Duan, Yang Gao, Yuan-Da Cheng and Chun-Fang Zhang

Department of Thoracic Surgery, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China; Department of Gastroenterology, Xiangya Third Hospital, Central South University, Changsha 410013, Hunan Province, China; Institute of Medical Science, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China

Correspondence: Chun-Fang Zhang (zhcf3801@csu.edu.cn)

Chromosome 14 ORF 166 (C14orf166), a protein involved in the regulation of RNA transcription and translation, has been reported to possess the potency to promote tumorigenesis; however, the role of C14orf166 in non-small-cell lung cancer (NSCLC) remains unknown. The purpose of the present study was to assess C14orf166 expression and its clinical significance in NSCLC. Immunohistochemical staining, quantitative real-time PCR (qRT-PCR), and Western blotting were used to detect the C14orf166 protein and mRNA expression levels in NSCLC tissues compared with adjacent normal tissues, as well as in NSCLC cell lines compared with normal human bronchial epithelial cells (HBE). Then, the correlations between the C14orf166 expression levels and the clinicopathological features of NSCLC were analyzed. Additionally, the Cox proportional hazard model was used to evaluate the prognostic significance of C14orf166. We found that C14orf166 expression increased in carcinoma tissues compared with their adjacent normal tissues at the protein ($P<0.001$) and mRNA levels ($P<0.001$). High expression of C14orf166 was significantly associated with the T stage ($P=0.006$), lymph node metastasis ($P=0.001$), advanced TNM stage ($P<0.001$), and chemotherapy ($P<0.001$). Moreover, according to the survival analysis, patients with overexpressed C14orf166 were inclined to experience a shorter overall survival and disease-free survival time ($P<0.001$). Multivariate COX analysis implied that C14orf166 was an independent prognostic biomarker. Taken together, our findings indicate that the overexpression of C14orf166 may contribute to the disease progression of NSCLC, represent a novel prognostic predictor and help high-risk patients make better decisions for subsequent therapy.

Introduction

Lung cancer is a well-known malignant disease, with the highest morbidity and mortality worldwide, moreover, nearly 40% patients were found with metastatic lesions at diagnosis [1,2]. Non-small-cell lung cancer (NSCLC) accounts for approximately 80% of total lung cancer pathological types, and it mainly consists of adenocarcinoma and squamous cell carcinoma [3]. Surgery is the main treatment for lung cancer, and adjuvant chemotherapy has gradually become common in patients with proper indications post-operation. Cisplatin is generally recommended for the treatment of advanced NSCLC; however, the efficacy of cisplatin is increasingly unsatisfactory because of the emergence of drug resistance, resulting in a 5-year survival rate that is still less than 15% [4,5]. Further investigations to explore the underlying mechanisms of NSCLC and to find novel biomarkers and therapeutic targets are needed to change this clinical dilemma.

Chromosome 14 ORF 166 (C14orf166), also known as CGI-99, CGI99, CLE, CLE7, LCRP369, or RLLM1, is a 28-kDa protein located in the nucleus and in the cytoplasm, while its conserved
gene is located on chromosome 14 at 14q22.1 [6]. As a component of nuclear and cytoplasmic protein complexes, C14orf166 was first found to be involved in viral RNA replication and transcriptional activation during influenza A virus infection through stimulating host RNAP II and viral RNA polymerase activities [7,8]. Then, C14orf166 was reported to act as a shuttling protein that helps substances involved in RNA metabolism shuttle between the nuclei and the cytoplasm. Furthermore, C14orf166 interacts with RNAP II and regulates RNA transcription directly, indicating a vital role of C14orf166 in cell growth and organ development [9]. It has been demonstrated that C14orf166 is responsible for nearly half of the mRNA translation participating in the cell cycle; therefore, the deletion of C14orf166 induces a loss of major cellular function [10]. In addition to its role in RNA metabolism as a binding partner of JAK2, C14orf166 is also involved in signal transduction, specifically through the signal transducer and activator of transcription 3 (STAT3 pathway), which is thought to regulate part of the downstream oncogenes shared by β-catenin [11]. It has been reported that the excessive activation of STAT3 participates in the pathogenesis of considerable tumors [12-14]. In esophagus carcinoma cells, overexpressed C14orf166 has been reported to activate the abnormal JAK2/STAT3 signaling pathway by acting as a JH2-interacting protein, which induces excessive function, initiating carcinogenesis [15-17]. Additionally, along with our previous research in esophagus squamous cell carcinoma [18], C14orf166 is found to be overexpressed in several tumor tissues [19-22]; however, the role of C14orf166 in NSCLC is unknown, and this present study aims to clarify this potency.

In the present study, we compared the expression of C14orf166 in cancerous tissues and cells with their respective normal controls at the protein and mRNA levels with immunohistochemistry (IHC), Western blot analysis, and quantitative real-time PCR (qRT-PCR). Furthermore, we explored the relationship between C14orf166 expression and the clinicopathological features and prognosis in NSCLC patients (NSCLCs).

**Materials and methods**

**Ethical statement**

Written informed consent was obtained from all the participants, and the study protocol was approved by the ethics committee of Xiangya Hospital, Central South University.

**Clinical samples and cell lines**

NSCLC tissues and paired normal lung tissues were obtained from 125 patients (median age: 60 years, range: 39–76 years) who underwent lung resection between July 2010 and December 2012 at Xiangya Hospital in Central South University. There were 32 women and 93 men enrolled in our present study. None of the patients had a history of previous malignancies, chemotherapy, or radiotherapy before sampling. The clinical and pathological data were complete and reliable. Tumor differentiation and staging was classified according to the eighth edition of TNM classification of UICC. One part of each sample was immediately snap-frozen in liquid nitrogen and was stored at −80°C for RNA and protein extraction. The other part of each sample was fixed in 10% neutral PB-buffered formalin (pH 7.4) for IHC. All the tissues were histologically confirmed by two pathologists.

The subjects were followed up every 3 months during the first post-operative year and at least 6 months afterward for survival and recurrence inquiry until death or until the end of the investigation.

Human NSCLC cell lines (A549, PC-9, and HTB182) and normal human bronchial epithelial cells (HBE) were obtained from Chinese Academy of Science Cell Bank (Shanghai, China). The cells were cultured and maintained in RPMI 1640 supplemented with 10% FBS), 100 U/ml penicillin and 100 μg/ml streptomycin in a humidified incubator with 5% CO₂ at a temperature of 37°C. All the culture materials were purchased from Gibco, U.S.A.

**qRT-PCR**

We followed the specific experimental details previously described [17]. The total RNA was extracted from the tissues or cells by using TRIzol (Invitrogen, U.S.A.) according to the manufacturer's protocol. After treatment with DNA-free (Ambion, U.S.A.) to remove the chromosomal DNA, the cDNA was synthesized using the Reverse Transcription Kit (Promega, U.S.A.) and was stored at −20°C until use. The mRNA expression levels of C14orf166 and β-actin were determined by qRT-PCR using the ABI PRISM 7500 sequence detector system (Applied Biosystems, U.S.A.). The primer sequences were sense/antisense: C14orf166: 5′-TCATATTGTACGCGCTTTTGA-3′/5′-TGACTGTTCTTGGTTTAGC-3′; and β-actin: 5′-TGACACCACCTTCTCAATGAG-3′/5′-GATAGCAGCGCTGGTAGCA-3′. The mRNA expression levels of the target genes were normalized to the β-actin signal. All the reactions were performed in triplicate using 20 μl samples containing 50 ng of cDNA. The reaction protocol involved heating for 10 min at 95°C, followed by 40
cycles of amplification (15 s at 95°C and 1 min at 60°C). The data were analyzed using the ABI PRISM 7500 Sequence Detection software. The relative expression of C14orf166 was described as $2^{-\Delta\Delta C_t}$.

**Western blotting analysis**

The cultured cells or tissues were harvested and lysed with RIPA lysis buffer (Beyotime, China) for 30 min on ice. After centrifugation at 12000 g for 20 min, the concentration of the proteins was measured using Bradford’s reagent (Bio-Rad Laboratories, U.S.A.). The protein samples were denatured by boiling for 10 min and were loaded on to SDS/PAGE (10% gel) for electrophoresis. The proteins were transferred on to a PVDF membrane (Millipore, U.S.A.), which was then incubated in the blocking solution (5% FBS) at room temperature for 1 h. The anti-C14orf166 (1:1000 (1 mg/ml), Proteintech, U.S.A.) was added into blocking solution and incubated at 4°C overnight. The membranes were subsequently incubated with HRP-labeled goat anti-rabbit IgG for 1.5 h at room temperature. Protein expression was normalized against GAPDH expression (1:1000, RD, U.S.A.). Bands were visualized by employing the BeyoECL Plus Detection System (Beyotime, China) and Bio-Rad Image Lab Software (CA, U.S.A.).

**Immunohistochemical staining**

The rapid PV two-step staining method with the following specifications was used: paraffin slice thickness of 5 μm, slices heated at 65°C for 60 min, dewaxed in xylene, rehydrated in an increasing diluted ethanol series, high-temperature antigen retrieval via microwave in 0.1 M citrate solution (pH 6.0) for 10 min, 3% H2O2 incubated at room temperature for 20 min, goat serum at room temperature incubated for 20 min, incubated anti-C14orf166 rabbit polyclonal antibody (1:100 (10 mg/ml), Proteintech, U.S.A.) at 4°C overnight, rewarmed the next day, incubated with the second anti-rabbit antibody at room temperature for 20 min, DAB coloration. Hematoxylin were mounted, and then microscopic examination. Results interpretation method: IHC was scored independently by two pathologists without knowledge of patient information, and any discrepancy was solved by consensus review. The score of immunoreactivity was performed by calculating the extent and intensity of staining positivity of cells in a semiquantitative manner. As described previously [23], the standards for evaluation included as following: positive stain intensity (0, negative; 1, weak; 2, moderate; 3, strong) and proportion of positive areas ($\leq 10\% = 1; 10–50\% = 2; \geq 50\% = 3$). The staining score was the multiplication of the previous two scores. Five high power fields in each specimen were selected randomly, and the final score is the average of the five scores. The samples were classified as weak staining when the final scores were 0–4 and when strong staining when more than 4.

**Statistical analysis**

SPSS software (version 16.0, Chicago, IL) was used for statistical analyses. Data were presented as mean ± S.D. from at least three separate experiments. Categorical variables were compared by χ² test or Fisher’s exact test. Continuous variables were compared using independent two sample t test. Multivariate analyses were performed by the Cox proportional hazard model. Survival curves were done by the Kaplan–Meier method (the log-rank test). All tests were two-tailed and $P<0.05$ was considered to be statistically significant.

**Results**

**C14orf166 was up-regulated in human NSCLC tissues and cell lines**

To investigate the protein expression of C14orf166 in NSCLCs, IHC staining was primitive used in 125 NSCLC primary tumor samples and in paired adjacent normal samples. Figure 1A shows that weak or no immunoreactivity was observed in the adjacent normal tissues; in contrast, C14orf166 protein was found to be highly expressed in both the carcinoma cell nuclei of lung adenocarcinoma and lung squamous carcinoma cells, and with the cytoplasmic reaction was occasionally displayed. According to previously mentioned standards [23], the strong staining rate of C14orf166 protein in the NSCLC group was 78.4% (98/125), while it was 11.2% (14/125) in the paired normal tissues group ($P<0.001$, Figure 1A). This discrepancy in the expression pattern of the C14orf166 protein was confirmed by Western blotting analysis (Figure 1D). Furthermore, C14orf166 mRNA expression was analyzed by qRT-PCR in 125 cases of NSCLCs and in their paired adjacent normal tissues. We found a similar tendency of C14orf166 expression at the mRNA level (Figure 1B). The overall average expression level of C14orf166 was markedly up-regulated (3.72 times) in tumor tissues than in adjacent normal tissues (Figure 1B). Moreover, high C14orf166 expression (more than two-fold namely, log2 (fold change) > 1) was observed in 75.2% cases (94/125) (Figure 1B and Table 1) when compared with C14orf166 mRNA expression in NSCLCs and those in paired adjacent normal tissues, suggesting that the overexpression of C14orf166 was a frequent event in human NSCLC.
Figure 1. C14orf166 was frequently overexpressed in NSCLC

(A) The expression of C14orf166 protein was assessed in normal and NSCLC tissues by IHC staining. Representative images of negative staining of C14orf166 in normal lung tissues (upper left), weak staining, and strong staining of C14orf166 in lung adenocarcinoma tissues (upper middle, upper right), weak staining, and strong staining of C14orf166 in lung squamous carcinoma tissues (lower left, lower middle). Compared with the normal lung tissues, the NSCLC tissues were detected to express more C14orf166 in the nuclei significantly (lower right). (B) The relative expression of C14orf166 mRNA in 125 NSCLC patients. Data were analyzed using a $-\Delta\Delta C_T$ (NSCLC/normal) approach and expressed as log$_2$ fold change ($-\Delta\Delta C_T$). (C) C14orf166 mRNA expression in NSCLC cell lines (A549, PC-9, and HTB182) and HBE. Each sample was analyzed in triplicate, and values are expressed as levels (mean ± S.D.) relative to those in HBE cells. (D,E) Representative images for C14orf166 protein in NSCLC tissues and cell lines compared with normal lung tissues and cell lines by Western blotting, respectively. (F) The positive correlation between C14orf166 mRNA levels and C14orf166 protein expression. Fold expression or fold change of C14orf166 mRNA was shown as $2^{-\Delta\Delta C_T}$, **$P<0.01$.**

C14orf166 expression in NSCLC cell lines and HBE was also detected by qRT-PCR and Western blotting. As shown in Figure 1C,E, compared with the expression in normal cells (HBE), C14orf166 mRNA and protein expression levels were significantly increased in human NSCLC cell lines (A549, PC-9, and HTB182).

Moreover, as Figure 1F shows, the relative expression of C14orf166 mRNA was positively associated with the IHC staining score, which indicated that C14orf166 was up-regulated in NSCLC both transcriptionally and translationally.
Table 1 Correlations between C14orf166 expression and clinicopathological variables of 125 cases of NSCLC

| Clinicopathological variables | n   | Low | High | P     |
|-------------------------------|-----|-----|------|-------|
| Age (years)                   |     |     |      |       |
| ≤60                           | 67  | 15  | 52   | 0.502 |
| >60                           | 58  | 16  | 42   |       |
| Gender                        |     |     |      |       |
| Female                        | 32  | 10  | 22   | 0.327 |
| Male                          | 93  | 21  | 72   |       |
| Smoking history (years)       |     |     |      |       |
| ≤10                           | 26  | 9   | 17   |       |
| >10                           | 99  | 22  | 77   | 0.193 |
| Pathological type             |     |     |      |       |
| Adenocarcinoma                | 56  | 15  | 41   | 0.643 |
| Squamous carcinoma            | 69  | 16  | 53   |       |
| Differentiation               |     |     |      |       |
| Well                          | 54  | 11  | 43   |       |
| Moderate                      | 43  | 15  | 28   |       |
| Poor                          | 28  | 5   | 23   | 0.162 |
| T classification              |     |     |      |       |
| T1                            | 24  | 10  | 14   | 0.006 |
| T2                            | 35  | 13  | 22   |       |
| T3                            | 44  | 6   | 38   |       |
| T4                            | 22  | 2   | 20   |       |
| N classification              |     |     |      |       |
| N0                            | 65  | 25  | 40   | 0.001 |
| N1                            | 32  | 4   | 28   |       |
| N2                            | 28  | 2   | 26   |       |
| TNM stage                     |     |     |      |       |
| I                             | 33  | 20  | 13   |       |
| II                            | 39  | 7   | 32   |       |
| III                           | 53  | 4   | 49   | -0.001|
| Chemotherapy                  |     |     |      |       |
| No                            | 69  | 7   | 62   |       |
| Yes                           | 56  | 24  | 32   | -0.001|

P-values < 0.05 are indicated in bold.

Elevated C14orf166 expression was related to clinicopathologic characters in NSCLC

The association between C14orf166 mRNA expression and the clinicopathological features of NSCLCs was explored by the χ² test or by Fisher’s exact test. As summarized in Table 1, the high expression of C14orf166 was significantly associated with T classification (P=0.006), lymph node metastasis (P=0.001), TNM stage (P<0.001), and chemotherapy (P<0.001). The high C14orf166 expression rate was 68.7% in females and 77.4% in males. However, there was no significant relationship between C14orf166 expression and variables such as age (P=0.502), gender (P=0.327), smoking history (P=0.193), pathological type (P=0.643), or tumor differentiation (P=0.162). A subgroup analysis revealed that overexpressed C14orf166 was associated with advanced stage and with lymph node metastasis (Figure 2A,B).

Overexpressed C14orf166 was associated with the poor prognosis of NSCLC

In the present study, we successfully followed up with 120 patients (loss rate is 4.0%), and the mean follow-up duration was 37.15 months (5–60 months). To assess the potential role of C14orf166 expression in NSCLC prognosis, a Kaplan–Meier survival analysis and log-rank test were performed. Expression of C14orf166 was tightly associated...
with survival time. The patients with overexpression of C14orf166 had much shorter overall survival time (median survival time, 32 compared with more than 60 months) \((P<0.001, \text{Figure 2C})\) and shorter disease-free survival (median survival time, 29 compared with more than 60 months) than those with low C14orf166 expression \((P<0.001, \text{Figure 2D})\).

To assess the feasibility of C14orf166 expression in predicting NSCLC prognosis, the Cox proportional hazards regression model was conducted. From multivariate survival analysis, T classification \((P<0.001)\), N classification \((P=0.001)\), TNM stage \((P=0.001)\), chemotherapy \((P=0.017)\), and C14orf166 expression \((P<0.001)\) reached significance in terms of overall survival \((\text{Table 2})\). For the analysis of disease-free survival time, T classification \((P=0.001)\), N classification \((P<0.001)\), TNM stage \((P=0.001)\), chemotherapy \((P=0.043)\), and C14orf166 expression \((P=0.001)\) reached significance in the multivariate survival analysis Cox proportional hazards regression model \((\text{Table 2})\).

### Discussion

As a protein located in the nucleus and in the cytoplasm, C14orf166 was found to be a transcriptional regulator related to the repression of the centrosome architecture \([6]\) and to be a shuttling protein, playing an important role in the regulation of cellular RNA expression through the transportation of RNAs between the nucleus and the cytoplasm \([10,24]\). RNAs combined with the binding complex, C14orf166–DDX1–HSPC117–FAM98B, are selected to be transported and promote expression \([25]\). The function of C14orf166 accounts for normal RNA transcription, mRNA expression, signal transduction, and even for important cellular phenotypes such as proliferation and apoptosis \([10]\). The overexpression of C14orf166 has been found to contribute to oncogenesis and to invasion behaviors in a variety of tumors \([19–22]\).

The present study took the lead to report that the overexpression of C14orf166 was associated with disease progression and poor prognosis in NSCLC. First, IHC staining displayed that C14orf166 protein expression was obviously increased in NSCLC tissues, while none or few positive reactants were found in the adjacent normal tissues. Furthermore, the statistical information revealed a significant increase in C14orf166 expression in carcinoma tissues
Table 2 Cox regression multivariate analysis of overall and disease-free survival in 120 patients with NSCLC

| Variables                        | Overall survival | Disease-free survival |
|----------------------------------|------------------|-----------------------|
|                                  | n                | HR (95% CI)           | P         | HR (95% CI)           | P         |
| Age (years)                      |                  |                       |           |                       |           |
| ≤60                              | 64               | 1                     |           | 1                     |           |
| >60                              | 56               | 1.60 (0.93–2.73)       | 0.089     | 1.45 (0.86–2.46)       | 0.164     |
| Gender                           |                  |                       |           |                       |           |
| Female                           | 30               | 1                     |           | 1                     |           |
| Male                             | 90               | 0.99 (0.54–1.81)       | 0.978     | 0.96 (0.53–1.71)       | 0.878     |
| Smoking history (years)          |                  |                       |           |                       |           |
| ≤10                              | 24               | 1                     |           | 1                     |           |
| >10                              | 96               | 1.50 (0.79–2.83)       | 0.216     | 1.37 (0.73–2.58)       | 0.331     |
| Pathological type                |                  |                       |           |                       |           |
| Adenocarcinoma                   | 53               | 1                     |           | 1                     |           |
| Squamous carcinoma               | 67               | 0.84 (0.50–1.39)       | 0.489     | 0.78 (0.47–1.29)       | 0.330     |
| Differentiation                  |                  |                       |           |                       |           |
| Well                             | 53               | 1                     |           | 1                     |           |
| Moderate                         | 43               | 0.73 (0.37–1.43)       | 0.358     | 0.71 (0.38–1.34)       | 0.291     |
| Poor                             | 24               | 1.36 (0.63–2.97)       | 0.435     | 1.27 (0.57–2.78)       | 0.560     |
| T classification                 |                  | <0.001                |           | 0.001                 |           |
| T1                               | 22               | 1                     |           | 1                     |           |
| T2                               | 33               | 0.64 (0.18–2.33)       | 0.502     | 0.96 (0.28–3.31)       | 0.952     |
| T3                               | 43               | 2.25 (0.69–7.27)       | 0.177     | 2.59 (0.80–8.40)       | 0.112     |
| T4                               | 22               | 9.38 (2.48–35.54)      | <0.001    | 8.04 (2.09–30.98)      | 0.002     |
| N classification                 |                  | <0.001                |           | <0.001                |           |
| N0                               | 64               | 1                     |           | 1                     |           |
| N1                               | 30               | 2.52 (0.82–7.77)       | 0.108     | 2.16 (0.71–6.51)       | 0.173     |
| N2                               | 26               | 12.55 (3.23–48.76)     | <0.001    | 9.58 (2.50–36.80)      | 0.001     |
| TNM stage                        |                  | 0.001                 |           | 0.001                 |           |
| I                                | 32               | 1                     |           | 1                     |           |
| II                               | 36               | 13.71 (3.22–58.34)     | <0.001    | 12.68 (3.28–49.11)     | <0.001    |
| III                              | 52               | 30.01 (3.92–229.59)    | <0.001    | 35.06 (4.74–259.31)    | <0.001    |
| Chemotherapy                     |                  |                       |           |                       |           |
| No                               | 66               | 1                     |           | 1                     |           |
| Yes                              | 54               | 0.44 (0.22–0.86)       | 0.017     | 0.50 (0.26–0.98)       | 0.043     |
| C14orf166 expression             |                  |                       |           |                       |           |
| Low                              | 28               | 1                     |           | 1                     |           |
| High                             | 92               | 4.88 (2.08–11.46)      | <0.001    | 4.01 (1.81–8.92)       | 0.001     |

P-values <0.05 are indicated in bold. HR, hazard ratio; CI, confidence interval.

Compared with adjacent normal tissues, and a similar tendency was observed by Western blotting. Second, qRT-PCR analysis also revealed that C14orf166 mRNA was overexpressed in most cases of NSCLC, which was positively associated with the IHC staining score, indicating that C14orf166 was up-regulated in NSCLC both transcriptionally and translationally, which was in accordance with the function of C14orf166. Moreover, we found that C14orf166 was constantly up-regulated in NSCLC cell lines. These results agree with our previous study of C14orf166 in esophagus squamous cell carcinoma [18], as well as in other previous studies [22,26].

The data in the present study also showed that C14orf166 may be a promising prognostic predictor of NSCLC. First, we explored the potential correlation between C14orf166 mRNA expression and the various clinicopathological characteristics of NSCLC patients, and we found that the increased expression of C14orf166 was nonsignificant in terms of age, gender, smoking history, and even tumor differentiation, but the study revealed a strong relationship with T stage, lymph node involvement, TNM stage and chemotherapy. It is worth mentioning that the expression of C14orf166 was undifferentiated in lung squamous carcinoma tissues and in lung adenocarcinoma lesions. Our data indicated that despite the tumor differentiation and pathological type, the higher expression of C14orf166 advanced the tumor progression, which is consistent with research in pancreatic cancer [21]. Lymph node involvement is an
indicator frequently used for disease condition evaluation as well as for outcome prediction in NSCLC, which is consistent with our present study. The patients with elevated expression of C14orf166 had significantly associated with shorter overall and disease-free survival times. In addition to T stage, N stage, TNM stage, and chemotherapy, our data showed that C14orf166 expression was also an independent prognostic predictor in NSCLC patients. As an adjuvant therapy, chemotherapy is used clinically to improve prognosis in NSCLC patients, and our information also displayed that the patients with increased C14orf166 expression tended to undertake chemotherapy, which can be explained by the high expression of C14orf166 that was significantly associated with the advanced TNM stage. The majority of patients undergoing chemotherapy experienced a high frequency of severe side effects; therefore, our present study on C14orf166 may benefit clinical decision-making in NSCLC patients. Though a recent study has explored the feasibility of detected C14orf166 in blood samples [20], further validation investigations are urgently needed to discover its role as a serum biomarker for early diagnosis and as a target for therapy design.

Dysfunction of signal pathways has been reported to be involved in tumor initiation as well as in progression for their crucial role associated with cellular function, such as proliferation, differentiation, survival, and apoptosis [27-30]. Consistent with other studies, our results implied that C14orf166 might participate in oncogenesis and tumor progression in NSCLC and that it might be attributed to the function of C14orf166 in cell division and signal transduction, in addition to its regulatory role in mRNA expression. It has been demonstrated that C14orf166 is associated with ninein in the centrosomes during cell division [31]. Howng et al.'s [32] research also confirms that C14orf166 may be involved and restricted to ninein phosphorylation during the cell cycle by co-operating with GSK-3β, which is thought to account for the formation and development of brain tumors. As an evolutionarily conserved serine/threonine kinase, GSK-3β phosphorylates β-catenin, which induces its degradation through ubiquitination and proteasomal activation in cytosol. It has been generally believed that abnormal GSK-3β-mediated functions are associated with carcinogenesis [33]. Excessive GSK-3β function, which is frequently observed in tumor initiation, promotes progression and contributes to drug resistance by harassing signaling pathways including the Wnt/β-catenin, PI3K-AKT-mTOR, and JAK2/STAT3 signaling pathways [34-36]. Aberrant β-catenin degradation by GSK-3β can promote lung carcinoma cells metastasis and spread [37-39]. The inhibition of GSK-3β induces β-catenin accumulation and plays a vital role in chemical agent-induced growth inhibition and apoptosis in lung cancer cells, such as tivantinib and dihydroartemisinin [40,41]. The disordered intracellular JAK2/STAT3 signaling pathway is frequent in many carcinomas and is related to malignant features; therefore, blocking of this pathway can help decrease tumor burden and to improve chemosensitivity. The inhibition of GSK-3β is crucial for xanthation to exert its anticancer properties in NSCLC, and the restraint of inherent activation of STAT3 enhances this function [42]. C14orf166 has been found to participate in the development of cervical cancer, which is thought to be involved in the abnormal JAK2/STAT3 pathway [22]. Along with the acylglycerol kinase, C14orf166 is identified as a JH2-interacting protein, which consecutively activates the JAK2/STAT3 signaling pathway to promote esophageal squamous cell generation and to enhance the cancer stem cell population [43]. Although our present study cannot reveal the innermost mechanism in NSCLC, the potential interpretation might be the exceptional signaling pathway, which is partly a consequence of the interaction of overexpressed C14orf166 and GSK-3β.

In conclusion, C14orf166 is up-regulated in NSCLC and is significantly correlated with T stage, N stage, TNM stage, chemotherapy, and overall and disease-free survival. The high expression of C14orf166 is significantly associated with a poor prognosis in advanced stage and in lymph node metastasis patients with NSCLC. C14orf166 is an independent prognostic biomarker for NSCLC patients, which may provide a wider perspective on NSCLC intervention, prevention, and treatment. Though these preliminary results show the potential role of C14orf166 in NSCLC, the underlying mechanism of C14orf166 in regulating oncogenesis, progression, metastasis, and prognosis still requires further investigation.

**Funding**

This work was supported by the National Youth Foundation of China [grant number 81702928]; the National Natural Scientific Foundation of China [grant number 81372515]; and the Science Funds for Young Scholar of Xiangya Hospital [grant number 2013Q02].

**Competing interests**

The authors declare that there are no competing interests associated with the manuscript.
Author contribution
Chun-Fang Zhang and Yan-wu Zhou contributed to the design and conceptions of the study, as well as the acquisition, analysis and interpretation of data, and writing; Rong Li and Chao-Jun Duan performed the research and contributed new reagents and analytic tools; Yang Gao and Yuan-Da Cheng mainly engaged in follow-up and primary data analysis.

Abbreviations
C14orf166, chromosome 14 ORF 166; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GSK-3β, Glycogen synthase kinase-3β; HBE, human bronchial epithelial cell; HRP, horseradish peroxidase; IHC, immunohistochemistry; JAK, Janus kinase; NSCLC, non-small-cell lung cancer; PI3K-AKT-mTOR, phosphatidylinositol-3-kinase-serine/threonine kinase-mammalian target of rapamycin; qRT-PCR, quantitative real-time PCR; RIPA, radio immunoprecipitation assay; STAT3, signal transducer and activator of transcription 3; TNM, Tumor Node Metastasis; UICC, Union for International Cancer Control.

References
1 Siegel, R., DeSantis, C., Virgo, K. et al. (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 62, 220–241, https://doi.org/10.3322/caac.21149
2 Tan, L., Hu, Y., Tao, Y. et al. (2016) Expression and copy number gains of the RET gene in 631 early and mid stage non-small cell lung cancer patients. Thorac. Cancer 9, 445–451, https://doi.org/10.1111/1759-7714.12603
3 He, D., Wang, J., Zhang, C. et al. (2015) Down-regulation of miR-675-5p contributes to tumor progression and development by targeting pro-tumorigenic GPR55 in non-small cell lung cancer. Mol. Cancer 14, 73, https://doi.org/10.1186/s12943-015-0342-0
4 Zang, H., Peng, J., Wang, W. and Fan, S. (2017) Roles of microRNAs in the resistance to platinum based chemotherapy in the non-small cell lung cancer. J. Cancer 8, 3856–3861, https://doi.org/10.7150/jca.21267
5 Heist, R.S. and Engelman, J.A. (2012) SnapShot: non-small cell lung cancer. Cancer Cell 21, 448e2, https://doi.org/10.1016/j.ccr.2012.03.007
6 Lupi, I., Bromian, K.W. and Tzou, S.C. (2009) Novel autoantigens in autoimmune hypophysitis. Clin. Endocrinol. (Oxf.) 69, 269–278, https://doi.org/10.1111/j.1365-2265.2008.03180.x
7 Rodriguez, A., Perez-Gonzalez, A. and Nieto, A. (2011) Cellular human CLE/C14orf166 protein interacts with influenza virus polymerase and is required for viral replication. J. Virol. 85, 12062–12066, https://doi.org/10.1128/JVI.00684-11
8 Natasya Naili, M.N., Hasnita, C.H., Shamim, A.K. et al. (2010) Chromosomal alterations in Malaysian patients with nasopharyngeal carcinoma analyzed by comparative genomic hybridization. Cancer Genet. Cytogenet. 203, 309–312, https://doi.org/10.1016/j.cancergen.2010.07.137
9 Elvira, G., Wasiak, S., Blandford, V. et al. (2006) Characterization of an RNA granule from developing brain. Mol. Cell. Proteomics 5, 635–651, https://doi.org/10.1074/mcp.M500255-MCP200
10 Huarte, M., Sanz-Ezquerro, J.J., Roncal, F., Ortín, J. and Nieto, A. (2001) PA subunit from influenza virus polymerase complex interacts with a cellular protein with homology to a family of transcriptional activators. J. Virol. 75, 8597–8604, https://doi.org/10.1128/JVI.75.18.8597-8604.2001
11 Zhang, J.X., Zhang, J., Yan, W. et al. (2013) Unique genome-wide map of TCF4 and STAT3 targets using ChIP-seq reveals their association with new molecular subtypes of glioblastoma. Neuro Oncol. 15, 279–289, https://doi.org/10.1093/neuonc/nos306
12 Johnston, P.A. and Grandis, J.R. (2011) STAT3 signaling: anticaner strategies and challenges. Mol. Interv. 11, 18–26, https://doi.org/10.1142/MI111.4
13 Armanious, H., Gelebart, P., Mackey, J. et al. (2010) STAT3 upregulates the protein expression and transcriptional activity of beta-catenin in breast cancer. Int. J. Clin. Exp. Pathol. 3, 654–664
14 Kawada, M., Seno, H., Uenoyma, Y. et al. (2006) Signal transducers and activators of transcription 3 activation is involved in nuclear accumulation of beta-catenin in colorectal cancer. Cancer Res. 66, 2913–2917, https://doi.org/10.1158/0008-5472.CAN-05-3460
15 Yu, H., Pardoll, D. and Jove, R. (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9, 798–809, https://doi.org/10.1038/nrc2734
16 Ernst, M. and Putoczki, T.L. (2012) STAT3: linking inflammation to (gastrointestinal) tumourogenesis. Clin. Exp. Pharmacol. Physiol. 39, 711–718, https://doi.org/10.1111/j.1440-1681.2011.05659.x
17 Fang, J., Chu, L., Li, C. et al. (2015) JAK2 inhibitor blocks the inflammation and growth of esophageal squamous cell carcinoma in vitro through the JAK/STAT3 pathway. Oncol. Rep. 33, 494–502, https://doi.org/10.3892/or.2014.3609
18 Zhou, Y.W., Li, R., Duan, C.J. et al. (2017) Expression and clinical significance of C14orf166 in esophageal squamous cell carcinoma. Mol. Med. Rep. 16, 605–612, https://doi.org/10.3892/mmr.2016.6056
19 Wang, J., Gu, Y., Wang, L. et al. (2007) HUPO BPP pilot study: a proteomics analysis of the mouse brain of different developmental stages. Proteomics 7, 4008–4015, https://doi.org/10.1002/pmc.200700341
20 Guo, J., Wang, W., Liao, P. et al. (2009) Identification of serum biomarkers for pancreatic adenocarcinoma by proteomic analysis. Cancer Sci. 100, 2292–2301, https://doi.org/10.1111/j.1349-7006.2009.01324.x
21 Cui, Y., Wu, J., Zong, M. et al. (2009) Proteomic profiling in pancreatic cancer with and without lymph node metastasis. Int. J. Cancer 124, 1614–1621, https://doi.org/10.1002/ijc.24163
22 Zhang, W., Ou, J., Lei, F. et al. (2015) C14orf166 overexpression is associated with pelvic lymph node metastasis and poor prognosis in uterine cervical cancer. Tumour Biol. 37, 369–379
23 Zou, Y.W., Zhang, H., Duan, C.J. et al. (2016) miR-675-5p enhances tumorigenesis and metastasis of esophageal squamous cell carcinoma by targeting REPS2. Oncotarget 7, 30730–30747
24 Schamel, K., Staeheli, P. and Hausmann, J. (2001) Identification of the immunodominant H-2K(k)-restricted cytotoxic T-cell epitope in the Borna disease virus nucleoprotein. J. Virol. 75, 8579–8588, https://doi.org/10.1128/JVI.75.18.8579-8588.2001

25 Perez-Gonzalez, A., Pazo, A., Navajas, R. et al. (2014) hCLE/C14orf166 associates with DDX1-HSPC117-FAM98B in a novel transcription-dependent shuttling RNA-transporting complex. PLoS ONE 9, e90957, https://doi.org/10.1371/journal.pone.0090957

26 Yang, L., Li, F., Lei, F. et al. (2015) Overexpression of chromosome 14 open reading frame 166 correlates with disease progression and poorer prognosis in human NPC. Tumour Biol. 36, 7977–7986, https://doi.org/10.1007/s13277-015-3518-8

27 Mukthavaram, R., Ouyang, X., Saklecha, R. et al. (2015) Effect of the JAK2/STAT3 inhibitor SAR317461 on human glioblastoma tumorspheres. J. Transl. Med. 13, 269, https://doi.org/10.1186/s12967-015-0627-5

28 Zhao, H., Guo, Y., Li, S. et al. (2015) A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway. Oncotarget 6, 31927–31943

29 Kong, Y., Si, L., Li, Y. et al. (2015) Analysis of mTOR gene aberrations in melanoma patients and evaluation of their sensitivity to PI3K-AKT-mTOR pathway inhibitors. Clin. Cancer Res. 22, 1018–1027

30 Huang, S.Q., Sun, B., Xiong, Z.P. et al. (2018) The dysregulation of tRNAs and tRNA derivatives in cancer. J. Exp. Clin. Cancer Res. 37, 101, https://doi.org/10.1186/s13046-018-0745-z

31 Andersen, J.S., Wilkinson, C.J., Mayor, T. et al. (2003) Proteomic characterization of the human centrosome by protein correlation profiling. Nature 426, 570–574, https://doi.org/10.1038/nature02166

32 Howng, S.L., Hsu, H.C., Cheng, T.S. et al. (2004) A novel ninein-interaction protein, CGI-99, blocks ninein phosphorylation by GSK3beta and is highly expressed in brain tumors. FEBS Lett. 566, 162–168, https://doi.org/10.1016/j.febslet.2004.04.024

33 Jacobs, K.M., Bhave, S.R., Ferraro, D.J. et al. (2012) GSK-3beta: a bifunctional role in cell death pathways. Int. J. Cell Biol.

34 Zhao, P., Li, Q., Shi, Z. et al. (2015) GSK-3beta regulates tumor growth and angiogenesis in human glioma cells. Oncotarget 6, 31901–31915, https://doi.org/10.18632/oncotarget.5043

35 Gao, Y., Liu, Z., Zhang, X. et al. (2013) Inhibition of cytoplasmic GSK-3beta increases cisplatin resistance through activation of Wnt/beta-catenin signaling in A549/DDP cells. Cancer Lett. 336, 231–239, https://doi.org/10.1016/j.canlet.2013.05.005

36 Ohsugi, M., Abe, Y., Semba, K., Akiyama, T. and Yamamoto, T. (2008) Ajuba negatively regulates the Wnt signaling pathway by promoting GSK-3beta-mediated phosphorylation of beta-catenin. Oncogene 27, 274–284, https://doi.org/10.1080/0950222080193121044

37 Jacobs, K.M., Bhave, S.R., Ferraro, D.J. et al. (2012) GSK-3beta: a bifunctional role in cell death pathways. Int. J. Cell Biol. 2012, 930710, https://doi.org/10.1155/2012/930710

38 Zhao, P., Li, Q., Shi, Z. et al. (2015) GSK-3beta regulates tumor growth and angiogenesis in human glioma cells. Oncotarget 6, 31901–31915, https://doi.org/10.18632/oncotarget.5043